Johnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big market for drugs that are used to treat EGFR-positive non-small cell lung cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback